HC Wainwright & Co. Reiterates Buy on Jasper Therapeutics, Maintains $65 Price Target

Benzinga · 10/15 09:45
HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $65 price target.